Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT06885281 trial: what clinicians have said so far
A Study of ZL-1310 in Participants With Selected Solid Tumors
- NCT06885281 ↗
- Recruiting
- Zai Lab (Shanghai) Co., Ltd.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT06885281 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06885281 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Solid Tumors
- Interventions
- ZL-1310
- Arms
- Single Arm · Experimental
- Enrollment
- 166 (estimated)
- Primary outcomes
- Incidence of Treatment Emergent Adverse-Events in Phase 1b
- Incidence of Serious Adverse Events in Phase 1b
- Evaluate antitumor activity of ZL-1310 as a single agent in Phase 2
- Sponsor
- Zai Lab (Shanghai) Co., Ltd. with Zai Lab (US) LLC
- Start
- May 12, 2025
- Primary completion
- Aug 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06885281 · updated Aug 21, 2026